Acceleron Pharma (XLRN) Gets a Buy Rating from H.C. Wainwright

By Austin Angelo

H.C. Wainwright analyst Edward White maintained a Buy rating on Acceleron Pharma (XLRNResearch Report) today and set a price target of $68. The company’s shares closed last Monday at $44.65.

White wrote:

“We are lowering our price target to $68 from $69 due to the discontinuation of ACE-083 for FSHD. Our $68 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline, and estimated year-end cash.”

According to, White is a 5-star analyst with an average return of 18.2% and a 52.9% success rate. White covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Inc., Syndax Pharmaceuticals Inc, and Aeglea Biotherapeutics Inc.

Acceleron Pharma has an analyst consensus of Strong Buy, with a price target consensus of $60.38, a 38.8% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $71 price target.

See today’s analyst top recommended stocks >>

Based on Acceleron Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.86 million. In comparison, last year the company had a GAAP net loss of $28.94 million.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is neutral on the stock. Most recently, in July 2019, John Quisel, the EVP, Chief Business Officer of XLRN bought 8,908 shares for a total of $42,908.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.